Ország: Hollandia
Nyelv: holland
Forrás: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
LENALIDOMIDE
Betapharm Arzneimittel GmbH Kobelweg 95 D-86156 AUGSBURG (DUITSLAND)
L04AX04
LENALIDOMIDE
Capsule, hard
AMMONIA (E 527) ; CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSCARMELLOSE NATRIUM (E 468) ; GELATINE (E 441) ; IJZEROXIDE ZWART (E 172) ; INDIGOKARMIJN (E 132) ; KALIUMHYDROXIDE (E 525) ; LACTOSE 0-WATER ; MAGNESIUMSTEARAAT (E 470b) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK (E 904) ; TITAANDIOXIDE (E 171) ; ZWARTE INKT
Oraal gebruik
Lenalidomide
2019-07-15
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LENALIDOMIDE BETAPHARM 2,5 MG, HARDE CAPSULES LENALIDOMIDE BETAPHARM 5 MG, HARDE CAPSULES LENALIDOMIDE BETAPHARM 7,5 MG, HARDE CAPSULES LENALIDOMIDE BETAPHARM 10 MG, HARDE CAPSULES LENALIDOMIDE BETAPHARM 15 MG, HARDE CAPSULES LENALIDOMIDE BETAPHARM 20 MG, HARDE CAPSULES LENALIDOMIDE BETAPHARM 25 MG, HARDE CAPSULES lenalidomide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lenalidomide betapharm is and what it is used for 2. What you need to know before you take Lenalidomide betapharm 3. How to take Lenalidomide betapharm 4. Possible side effects 5. How to store Lenalidomide betapharm 6. Contents of the pack and other information 1 WHAT LENALIDOMIDE BETAPHARM IS AND WHAT IT IS USED FOR Lenalidomide betapharm contains the active substance ‘lenalidomide’. This medicine belongs to a group of medicines which affect how your immune system works. Lenalidomide betapharm is used in adults for • Multiple Myeloma • Follicular lymphoma MULTIPLE MYELOMA Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys. Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a ‘response’. Newly diagnosed multiple myeloma - in patients who have had a bone marrow transplant Lenalidomide betapharm is used on Olvassa el a teljes dokumentumot
SAMENVATTING VAN DE PRODUCTKENMERKEN 1. NAME OF THE MEDICINAL PRODUCT Lenalidomide betapharm 2,5 mg, harde capsules Lenalidomide betapharm 5 mg, harde capsules Lenalidomide betapharm 7,5 mg, harde capsules Lenalidomide betapharm 10 mg, harde capsules Lenalidomide betapharm 15 mg, harde capsules Lenalidomide betapharm 20 mg, harde capsules Lenalidomide betapharm 25 mg, harde capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 2.5 mg of lenalidomide. Each capsule contains 5 mg of lenalidomide. Each capsule contains 7.5 mg of lenalidomide. Each capsule contains 10 mg of lenalidomide. Each capsule contains 15 mg of lenalidomide. Each capsule contains 20 mg of lenalidomide. Each capsule contains 25 mg of lenalidomide. Excipient(s) with known effect: Each capsule contains 33.2 mg of lactose. Each capsule contains 66.4 mg of lactose. Each capsule contains 99.7 mg of lactose. Each capsule contains 132.9 mg of lactose. Each capsule contains 199.3 mg of lactose. Each capsule contains 265.8 mg of lactose. Each capsule contains 332.2 mg of lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Opaque white body and opaque green to light green cap, with a length of approximately14.3 mm, marked “L9NL” and “2.5”. Opaque white body and opaque white cap, with a length of approximately 18.0 mm, marked “L9NL” and “5”. Opaque white body and opaque yellow cap, with a length of approximately 18.0 mm, marked “L9NL” and “7.5”. Opaque yellow body and opaque green to light green cap, with a length of approximately 21.7 mm, marked “L9NL” and “10”. Opaque white body and opaque blue to light blue cap, with a length of approximately 21.7 mm, marked “L9NL” and “15”. Opaque blue to light blue body and opaque green to light green cap, with a length of approximately 21.7 mm, marked “L9NL” and “20”. Opaque white body and opaque white cap, with a length of approximately 21.7 mm, marked “L9NL” and “25”. 4. CLINICAL PARTICULARS 4.1 Olvassa el a teljes dokumentumot